A detailed history of Morgan Stanley transactions in Biovie Inc. stock. As of the latest transaction made, Morgan Stanley holds 12,369 shares of BIVI stock, worth $34,262. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,369
Previous 24,601 49.72%
Holding current value
$34,262
Previous $13,000 69.23%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Oct 17, 2024

SELL
$0.4 - $0.56 $4,892 - $6,849
-12,232 Reduced 49.72%
12,369 $4,000
Q2 2024

Aug 14, 2024

SELL
$0.4 - $0.56 $4,892 - $6,849
-12,232 Reduced 49.72%
12,369 $4,000
Q1 2024

Oct 17, 2024

BUY
$0.53 - $1.89 $6,482 - $23,118
12,232 Added 98.89%
24,601 $13,000
Q1 2024

Aug 16, 2024

SELL
$0.53 - $1.89 $30,964 - $110,421
-58,424 Reduced 70.37%
24,601 $13,000
Q1 2024

May 15, 2024

SELL
$0.53 - $1.89 $30,964 - $110,421
-58,424 Reduced 70.37%
24,601 $13,000
Q4 2023

Aug 16, 2024

BUY
$1.22 - $5.24 $86,200 - $370,237
70,656 Added 571.23%
83,025 $104,000
Q4 2023

Feb 13, 2024

BUY
$1.22 - $5.24 $33,791 - $145,137
27,698 Added 50.06%
83,025 $104,000
Q3 2023

Nov 15, 2023

BUY
$2.75 - $5.17 $50,941 - $95,769
18,524 Added 50.33%
55,327 $188,000
Q2 2023

Aug 14, 2023

BUY
$4.09 - $8.29 $38,625 - $78,290
9,444 Added 34.52%
36,803 $158,000
Q1 2023

May 15, 2023

BUY
$4.89 - $10.53 $24,503 - $52,765
5,011 Added 22.42%
27,359 $221,000
Q4 2022

Feb 14, 2023

BUY
$3.86 - $42.0 $78,145 - $850,290
20,245 Added 962.67%
22,348 $173,000
Q3 2022

Nov 14, 2022

BUY
$1.38 - $25.6 $832 - $15,436
603 Added 40.2%
2,103 $5,000
Q1 2022

May 13, 2022

SELL
$2.74 - $5.65 $5 - $11
-2 Reduced 0.13%
1,500 $7,000
Q4 2021

Feb 14, 2022

BUY
$4.41 - $6.99 $6,271 - $9,939
1,422 Added 1777.5%
1,502 $7,000
Q3 2021

Nov 15, 2021

BUY
$6.69 - $16.93 $535 - $1,354
80 New
80 $1,000

Others Institutions Holding BIVI

About BIOVIE INC.


  • Ticker BIVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,165,300
  • Market Cap $83.6M
  • Description
  • BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...
More about BIVI
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.